-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。当社は、複数の短期的な逆風によって株価収益率が圧縮されたことを反映して、12ヶ月目標株価を294ドルから245ドルに引き下げます。2026年度および2027年度の1株当たり利益(EPS)予想は、それぞれ17.51ドルと19.97ドルで据え置きます。株価収益率の圧縮は、いくつかの重要な懸念事項を反映しています。第一に、部品コストの上昇による利益率への圧力は、少なくとも2026年度上半期まで継続する可能性が高く、売上高が増加する一方で収益性を圧迫するでしょう。第二に、主要な最終市場におけるオーガニック需要は依然として不均一であり、先行き不透明感を生み出しています。第三に、当社の高水準の負債は、財務上の柔軟性を制限し、金利変動に対する感応度を高めています。最後に、経営陣がコスト削減戦略を策定しつつ、競争が激化する市場環境において市場シェアの維持を図る中で、事業遂行リスクは依然として高いままです。利益率の安定化と需要見通しの改善を示すより明確な証拠が得られるまでは、より保守的な評価手法が賢明であると考えます。
Related Articles
Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23
AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell
Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%
Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision
Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.